Skip to main content

REM Sleep Behavior Disorder

3
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
2
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
2
IdebenonePhase 2/31 trial
RasagilinePhase 2/31 trial
Active Trials
NCT04152655Withdrawn0Est. Jan 2023
NCT05611372Withdrawn0Est. Dec 2026
Syntara
SyntaraAustralia - Frenchs Forest
1 program
1
PXS-4728Phase 21 trial
Active Trials
NCT05904717Active Not Recruiting40Est. Jan 2026
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
North American Prodromal Synucleinopathy ConsortiumN/A1 trial
North American Prodromal Synucleinopathy Consortium Stage 2N/A1 trial
Active Trials
NCT03623672Enrolling By Invitation500Est. Jul 2026
NCT05826457Recruiting500Est. May 2025
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
North American Prodromal Synucleinopathy Consortium Stage 2N/A
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
Sodium OxybatePHASE_41 trial
Active Trials
NCT04006925Completed24Est. Feb 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Jazz PharmaceuticalsSodium Oxybate
UNION therapeuticsRasagiline
UNION therapeuticsIdebenone
SyntaraPXS-4728
Angeles TherapeuticsNorth American Prodromal Synucleinopathy Consortium Stage 2
Angeles TherapeuticsNorth American Prodromal Synucleinopathy Consortium

Clinical Trials (6)

Total enrollment: 1,064 patients across 6 trials

NCT04006925Jazz PharmaceuticalsSodium Oxybate

Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

Start: Sep 2019Est. completion: Feb 202224 patients
Phase 4Completed
NCT05611372UNION therapeuticsRasagiline

Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

Start: Jan 2023Est. completion: Dec 20260
Phase 2/3Withdrawn
NCT04152655UNION therapeuticsIdebenone

A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease

Start: Jan 2020Est. completion: Jan 20230
Phase 2/3Withdrawn
NCT05904717SyntaraPXS-4728

Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

Start: Nov 2023Est. completion: Jan 202640 patients
Phase 2Active Not Recruiting
NCT05826457Angeles TherapeuticsNorth American Prodromal Synucleinopathy Consortium Stage 2

North American Prodromal Synucleinopathy Consortium Stage 2

Start: Aug 2022Est. completion: May 2025500 patients
N/ARecruiting
NCT03623672Angeles TherapeuticsNorth American Prodromal Synucleinopathy Consortium

North American Prodromal Synucleinopathy Consortium

Start: Aug 2018Est. completion: Jul 2026500 patients
N/AEnrolling By Invitation

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,064 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.